[144] Assurant, Inc. SEC Filing
Rhea-AI Filing Summary
Assurant, Inc. (AIZ) filed a Form 144 reporting a proposed sale of 3,900 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 08/12/2025 and an aggregate market value of $813,256.47. The filing shows 50,459,211 shares outstanding.
The securities were acquired through restricted stock vesting under a registered plan on 07/15/2023 (1,100 shares), 03/16/2025 (415 shares), 03/16/2024 (1,810 shares) and 03/16/2022 (575 shares), with consideration listed as services rendered. The notice also records a prior sale of 1,000 shares on 05/16/2025 for $201,926.40. The filer attests they are not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider intends to sell 3,900 AIZ shares (~$813k) via Morgan Stanley; prior 1,000-share sale occurred in May 2025.
The filing is a routine Form 144 notification of a proposed sale by an insider or associated person. Key facts are the lot size (3,900 shares), the broker (Morgan Stanley Smith Barney LLC), the approximate sale date (08/12/2025) and the reported aggregate market value ($813,256.47). The securities were received via restricted stock vesting across multiple dates with consideration described as services rendered. From a market-impact perspective, the filing documents insider selling but does not disclose any non-public operational issues.
TL;DR: This Form 144 documents standard insider selling and contains the required representations; it raises governance transparency but no disclosed red flags.
The filer provides acquisition history showing awards vested under a registered plan on specified dates and affirms no knowledge of undisclosed material adverse information. The presence of a prior sale on 05/16/2025 is disclosed with proceeds. The form fulfills disclosure obligations under Rule 144 and Rule 10b5-1-related representation language is included. There is no disclosure here of governance changes, regulatory issues, or material adverse events.